JP2012523411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523411A5 JP2012523411A5 JP2012504645A JP2012504645A JP2012523411A5 JP 2012523411 A5 JP2012523411 A5 JP 2012523411A5 JP 2012504645 A JP2012504645 A JP 2012504645A JP 2012504645 A JP2012504645 A JP 2012504645A JP 2012523411 A5 JP2012523411 A5 JP 2012523411A5
- Authority
- JP
- Japan
- Prior art keywords
- dodecahedron
- blm
- molecular weight
- bleomycin
- low molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 92
- 229960001561 bleomycin Drugs 0.000 claims description 90
- 108010006654 Bleomycin Proteins 0.000 claims description 85
- 239000002245 particle Substances 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 63
- 230000001225 therapeutic effect Effects 0.000 claims description 54
- 241000701161 unidentified adenovirus Species 0.000 claims description 53
- 239000000126 substance Substances 0.000 claims description 52
- 239000013598 vector Substances 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 235000018102 proteins Nutrition 0.000 claims description 28
- 101710173835 Penton protein Proteins 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 238000009739 binding Methods 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 14
- 230000001472 cytotoxic effect Effects 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 12
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 239000003966 growth inhibitor Substances 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 150000001718 carbodiimides Chemical class 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 7
- 108010015899 Glycopeptides Proteins 0.000 claims description 7
- 102000002068 Glycopeptides Human genes 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- 108700004675 bleomycetin Proteins 0.000 claims description 5
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000005538 encapsulation Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 4
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 claims description 4
- 108700025771 adenovirus penton Proteins 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 230000001938 anti-toxoplasmal effect Effects 0.000 claims description 4
- 230000001099 anti-trypanosomal effect Effects 0.000 claims description 4
- 239000000924 antiasthmatic agent Substances 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 4
- 238000010382 chemical cross-linking Methods 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 229960003350 isoniazid Drugs 0.000 claims description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 229960003279 thiopental Drugs 0.000 claims description 4
- 238000005199 ultracentrifugation Methods 0.000 claims description 4
- 230000000398 anti-amebic effect Effects 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 208000034712 Rickettsia Infections Diseases 0.000 claims 1
- 206010061495 Rickettsiosis Diseases 0.000 claims 1
- 230000002223 anti-pathogen Effects 0.000 claims 1
- 230000002365 anti-tubercular Effects 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 61
- 239000000523 sample Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000002296 dynamic light scattering Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 210000003855 cell nucleus Anatomy 0.000 description 7
- 230000001775 anti-pathogenic effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 101710145505 Fiber protein Proteins 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000004254 Ammonium phosphate Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000008001 CAPS buffer Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 4
- 235000019289 ammonium phosphates Nutrition 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000001088 anti-asthma Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000002022 anti-cellular effect Effects 0.000 description 3
- 230000002050 anti-rickettsial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000000814 tuberculostatic agent Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000045 antileishmanial agent Substances 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- -1 bleomycin Chemical compound 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108700008900 iron bleomycin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL387780A PL222496B1 (pl) | 2009-04-10 | 2009-04-10 | Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną |
| PLP-387780 | 2009-04-10 | ||
| PCT/PL2010/000026 WO2010117287A2 (en) | 2009-04-10 | 2010-04-09 | A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015179964A Division JP2016053026A (ja) | 2009-04-10 | 2015-09-11 | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523411A JP2012523411A (ja) | 2012-10-04 |
| JP2012523411A5 true JP2012523411A5 (enExample) | 2014-12-18 |
| JP5841045B2 JP5841045B2 (ja) | 2016-01-06 |
Family
ID=42752950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504645A Expired - Fee Related JP5841045B2 (ja) | 2009-04-10 | 2010-04-09 | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 |
| JP2015179964A Pending JP2016053026A (ja) | 2009-04-10 | 2015-09-11 | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015179964A Pending JP2016053026A (ja) | 2009-04-10 | 2015-09-11 | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8765666B2 (enExample) |
| EP (1) | EP2437787B1 (enExample) |
| JP (2) | JP5841045B2 (enExample) |
| BR (1) | BRPI1016056A2 (enExample) |
| PL (1) | PL222496B1 (enExample) |
| WO (1) | WO2010117287A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014212722A (ja) * | 2013-04-24 | 2014-11-17 | 学校法人加計学園 | 八面体構造を有するｂ型肝炎ウイルス様粒子結晶 |
| US12600956B2 (en) | 2015-12-17 | 2026-04-14 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
| US10316295B2 (en) | 2015-12-17 | 2019-06-11 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
| RS64059B1 (sr) * | 2016-03-31 | 2023-04-28 | The European Molecular Biology Laboratory | Protein adenoviralnog omotača izveden iz vehikuluma za isporuku |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741087B1 (fr) * | 1995-11-13 | 1998-01-09 | Commissariat Energie Atomique | Complexe proteique dodecaedrique adenoviral, procede de preparation, composition le contenant et ses applications |
| FR2747681B1 (fr) * | 1996-04-18 | 1998-06-19 | Commissariat Energie Atomique | Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications |
| WO1997018317A1 (fr) * | 1995-11-13 | 1997-05-22 | Commissariat A L'energie Atomique | Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications |
| NZ537003A (en) * | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| RU2325202C2 (ru) * | 2002-07-19 | 2008-05-27 | Цитос Байотекнолоджи Аг | Конъюгаты грелин-носитель |
| US7427395B2 (en) * | 2002-11-01 | 2008-09-23 | Genomidea Inc. | Chemotherapeutic agent-incorporated pharmaceutical preparation |
| WO2005094878A1 (ja) * | 2004-03-31 | 2005-10-13 | Genomidea Inc. | 抗腫瘍作用を有する組成物 |
| WO2007016864A1 (fr) * | 2005-08-08 | 2007-02-15 | Xun Hu | Utilisation de fructus schisandrae et d'extraits de cette substance dans le but de prevenir et d'attenuer les effets toxiques et secondaires de medicaments anti-neoplasiques |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| BRPI0616446A2 (pt) * | 2005-09-28 | 2011-06-21 | Cytos Biotechnology Ag | composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento |
-
2009
- 2009-04-10 PL PL387780A patent/PL222496B1/pl unknown
-
2010
- 2010-04-09 BR BRPI1016056A patent/BRPI1016056A2/pt not_active Application Discontinuation
- 2010-04-09 WO PCT/PL2010/000026 patent/WO2010117287A2/en not_active Ceased
- 2010-04-09 US US13/263,632 patent/US8765666B2/en not_active Expired - Fee Related
- 2010-04-09 JP JP2012504645A patent/JP5841045B2/ja not_active Expired - Fee Related
- 2010-04-09 EP EP10726635.5A patent/EP2437787B1/en active Active
-
2015
- 2015-09-11 JP JP2015179964A patent/JP2016053026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Charge‐reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment | |
| Li et al. | Discovery and characterization of a peptide that enhances endosomal escape of delivered proteins in vitro and in vivo | |
| Choi et al. | Cyclic RGD peptide incorporation on phage major coat proteins for improved internalization by HeLa cells | |
| Martino et al. | Single-point mutations in Qβ virus-like particles change binding to cells | |
| Li et al. | Intracellular antibody delivery mediated by lipids, polymers, and inorganic nanomaterials for therapeutic applications | |
| WO2014126146A1 (ja) | 未分化細胞除去方法 | |
| Zhang et al. | In vitro preparation of uniform and nucleic acid free hepatitis B core particles through an optimized disassembly-purification-reassembly process | |
| JP2016053026A (ja) | 医薬品送達用のウイルス様粒子ベクター、その製造方法、使用、及び医薬組成物 | |
| EA035308B1 (ru) | Применение vlp из вируса полиомы человека для доставки лекарственного средства в цнс и способ лечения заболевания цнс | |
| US10669313B2 (en) | Multitarget-directed bio-inorganic hybrid structure | |
| Kitagishi et al. | Intracellular delivery of adamantane-tagged small molecule, proteins, and liposomes using an octaarginine-conjugated β-cyclodextrin | |
| Ding et al. | Substance P containing peptide gene delivery vectors for specifically transfecting glioma cells mediated by a neurokinin-1 receptor | |
| CN101143895A (zh) | 一种具有肿瘤靶向性的多肽及其制备方法 | |
| Anderson et al. | N-glycan targeted gene delivery to the dendritic cell SIGN receptor | |
| US11241393B2 (en) | Organosilicon carriers for use in treating infections and/or diseases caused by SARS viruses | |
| Shi et al. | Genetic fusion of transacting activator of transcription peptide to cyclized green fluorescence protein improves stability, intracellular delivery, and tumor retention | |
| Ranka et al. | Fibronectin-binding nanoparticles for intracellular targeting addressed by B. burgdorferi BBK32 protein fragments | |
| KR100563942B1 (ko) | 분자 물질의 모듈 운반 시스템 및 그의 제조 방법 및 용도 | |
| EP3231441A1 (en) | Novel protein structure produced by effective antibody used for immunization | |
| KR20250043339A (ko) | 활성 성분의 표적화 전달을 위한 지질 마이크로버블 | |
| PL222497B1 (pl) | Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej | |
| Gonçalves et al. | Immunogen display on virus-like particles assembled from redesigned transcription activator-like effector proteins and nucleic acids: Activation of antigen-presenting cells | |
| JP5299922B2 (ja) | Ｈｂ−ｅｇｆ結合性タンパク質複合体 | |
| Pho | Surface Engineering of Protein Nanoparticles for Intranasal Delivery | |
| Yin et al. | α-Helical peptides: design strategies and recent advances in biomedical applications |